Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $17.22 Average Target Price from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $17.5556.

ADPT has been the topic of a number of recent analyst reports. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. JPMorgan Chase & Co. increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday. BTIG Research boosted their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $15.77 on Wednesday. The company has a market capitalization of $2.41 billion, a P/E ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies has a 1-year low of $6.26 and a 1-year high of $20.76. The firm’s 50 day simple moving average is $17.03 and its two-hundred day simple moving average is $15.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 48.73%. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. During the same period in the prior year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was up 51.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Adaptive Biotechnologies will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other news, insider Sharon Benzeno sold 308,477 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was sold at an average price of $16.91, for a total transaction of $5,216,346.07. Following the completion of the transaction, the insider owned 296,791 shares in the company, valued at $5,018,735.81. This trade represents a 50.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Chad M. Robins sold 124,998 shares of Adaptive Biotechnologies stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $18.94, for a total value of $2,367,462.12. Following the completion of the sale, the chief executive officer directly owned 2,709,241 shares in the company, valued at $51,313,024.54. This trade represents a 4.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 1,612,461 shares of company stock valued at $27,754,413. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Adaptive Biotechnologies

Several institutional investors have recently added to or reduced their stakes in ADPT. Brighton Jones LLC boosted its position in Adaptive Biotechnologies by 3.1% during the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after purchasing an additional 700 shares in the last quarter. Bouvel Investment Partners LLC lifted its position in shares of Adaptive Biotechnologies by 2.2% during the third quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after buying an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Adaptive Biotechnologies by 3.1% during the second quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after buying an additional 910 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Adaptive Biotechnologies by 1.0% in the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after buying an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors grew its position in shares of Adaptive Biotechnologies by 7.6% in the 2nd quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after buying an additional 1,119 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.